Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
This study has been withdrawn prior to enrollment.
(Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.)
William Beaumont Hospitals
First Posted: October 14, 2009
Last Update Posted: October 2, 2017
Information provided by (Responsible Party):
Pam Marcovitz, MD, William Beaumont Hospitals
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|